Sugi Predict

Sugi Predict / Compounds / SCHEMBL1498367

SCHEMBL1498367

SCHEMBL1498367

COC(=O)C1CC(OS(C)(=O)=O)C1

nearest known ligand 0.46

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ TP53 P04637 1/20 0.46
▸ CHRNB2 P17787 2/20 0.46
▸ CHRNA4 P43681 2/20 0.46
▸ CHRNB4 P30926 1/20 0.46
▸ CHRNA3 P32297 1/20 0.46
▸ CHRNA7 P36544 1/20 0.46
▸ MMP2 P08253 2/20 0.36
▸ ANPEP P15144 2/20 0.36
▸ BRD4 O60885 1/20 0.34
▸ PKM P14618 1/20 0.33
▸ SMN1; SMN2 Q16637 2/20 0.33
▸ ALDH1A1 P00352 1/20 0.32
▸ MAPT P10636 1/20 0.32
▸ HPGD P15428 1/20 0.32
▸ NPSR1 Q6W5P4 1/20 0.32
▸ HSD17B10 Q99714 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17293401 1.00 TP53 (0.46) TP53CHRNB2CHRNA4CHRNB4CHRNA3
SCHEMBL21222682 1.00 TP53 (0.46) TP53CHRNB2CHRNA4CHRNB4CHRNA3
SCHEMBL19714840 0.87 TP53 (0.46) TP53CHRNB2CHRNA4CHRNB4CHRNA3
SCHEMBL6913321 0.87 TP53 (0.46) TP53CHRNB2CHRNA4CHRNB4CHRNA3
SCHEMBL1139874 0.87 TP53 (0.46) TP53CHRNB2CHRNA4CHRNB4CHRNA3
SCHEMBL19714838 0.87 TP53 (0.46) TP53CHRNB2CHRNA4CHRNB4CHRNA3
SCHEMBL4088870 0.84 TP53 (0.46) TP53CHRNB2CHRNA4CHRNB4CHRNA3
SCHEMBL765277 0.84 TP53 (0.46) TP53CHRNB2CHRNA4CHRNB4CHRNA3
SCHEMBL4088867 0.84 TP53 (0.46) TP53CHRNB2CHRNA4CHRNB4CHRNA3
SCHEMBL10476737 0.84 TP53 (0.46) TP53CHRNB2CHRNA4CHRNB4CHRNA3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 78 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4709716-A1 ISOXAZOLIDINES AS RIPK1 INHIBITORS AND USE THEREOF GENZYME CORPORATION (US) 2026-03-18 — — EP disclosed
WO-2024233554-A1 ISOXAZOLIDINES AS RIPK1 INHIBITORS AND USE THEREOF GENZYME CORPORATION (US) 2024-11-14 — — WO disclosed
US-12012390-B2 Flavone compounds for the treatment and prophylaxis of hepatitis B virus disease HOFFMANN-LA ROCHE INC. (US) 2024-06-18 — — US disclosed
EP-4333899-A1 COMPOUNDS FOR TARGETING DEGRADATION OF BRUTON'S TYROSINE KINASE Biogen MA Inc. (US) 2024-03-13 — — EP disclosed
CN-117580592-A Compounds for targeting bruton's tyrosine kinase degradation 渤健马萨诸塞州股份有限公司 2024-02-20 — — CN disclosed
EP-4313955-A1 PYRIMIDINE DERIVATIVES USEFUL AS LRRK2 KINASE INHIBITORS Halia Therapeutics, Inc. (US) 2024-02-07 — — EP disclosed
CN-117355507-A Pyrimidine derivatives as LRRK2 kinase inhibitors 哈利亚治疗公司 2024-01-05 — — CN disclosed
CN-112601743-B Flavone compounds for the treatment and prevention of hepatitis b virus diseases 豪夫迈·罗氏有限公司 2023-12-19 — — CN disclosed
EP-3849966-B1 FLAVONE COMPOUNDS FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS DISEASE HOFFMANN LA ROCHE (CH) 2023-10-25 — — EP disclosed
EP-4259128-A1 IRAK DEGRADERS AND USES THEREOF Kymera Therapeutics, Inc. (US) 2023-10-18 — — EP disclosed
WO-2011035159-A1 ARYL SULPHONE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS ZALICUS PHARMACEUTICALS LTD. (CA) 2011-03-24 — — WO disclosed
WO-2011035159-A1 ARYL SULPHONE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS ZALICUS PHARMACEUTICALS LTD. (CA) 2011-03-24 — — WO disclosed
US-7326699-B2 4-Amino-5-phenyl-7-cyclobutyl-pyrrolo(2,3-d)pyrimidine derivatives NOVARTIS AG (CH) 2008-02-05 — — US disclosed
CN-1264844-C 4-amino-5-phenyl-7-cyclobutyl-pyrrolo (2,3-D) pyrimidie derivatives NOVARTIS AG (CH) 2006-07-19 — — CN disclosed
EP-1390369-B1 4-AMINO-5-PHENYL-7-CYCLOBUTYL-PYRROLO(2,3-D)PYRIMIDINE DERIVATIVES NOVARTIS AG (CH) 2005-11-09 — — EP disclosed
CN-1531538-A 4-amino-5-phenyl-7-cyclobutyl-pyrrolo (2,3-D) pyrimidie derivatives ��˹��ŵ�� 2004-09-22 — — CN disclosed
US-20040180911-A1 4-Amino-5-phenyl-7-cyclobutyl-pyrrolo(2,3-d)pyrimidine derivatives NOVARTIS AG (CH) 2004-09-16 — — US disclosed
EP-1390369-A1 4-AMINO-5-PHENYL-7-CYCLOBUTYL-PYRROLO(2,3-D)PYRIMIDINE DERIVATIVES Novartis AG (CH) 2004-02-25 — — EP disclosed
WO-2002092599-A1 4-AMINO-5-PHENYL-7-CYCLOBUTYL-PYRROLO (2,3-D) PYRIMIDINE DERIVATIVES NOVARTIS AG (CH) 2002-11-21 — — WO disclosed
WO-1997028161-A1 NOVEL PYRROLO[2,3-D]PYRIMIDINES AND THEIR USE AS TYROSINE KINASE INHIBITORS NOVARTIS AG (CH) 1997-08-07 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12012390-B2 Flavone compounds for the treatment and prophylaxis of hepatitis B virus disease PCNA, DNMT1, DNMT3B TP53 666/4885CHRNB2 4868/4885CHRNA4 4806/4885
US-20040180911-A1 4-Amino-5-phenyl-7-cyclobutyl-pyrrolo(2,3-d)pyrimidine derivatives TYMP, DPYD, TYMS TP53 114/4885CHRNB2 4823/4885CHRNA4 4749/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.